Ladiratuzumab vedotin - Seattle Genetics

Drug Profile

Ladiratuzumab vedotin - Seattle Genetics

Alternative Names: SGN-LIV1A

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seattle Genetics
  • Developer Genentech; Merck & Co; Quantum Leap Healthcare Collaborative; Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 12 Mar 2018 Phase-I/II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT03424005)
  • 27 Feb 2018 Phase-I/II clinical trials in Breast cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA (IV) (NCT03310957)
  • 15 Feb 2018 Hoffmann-La Roche and Seattle Genetics plans a phase I/II trial for Breast Cancer (Metastatic disease; Combination therapy, Late stage disease, Second line therapy or greater) in Australia, France, Germany, South Korea, Spain, United Kingdom, USA, in February 2018 (NCT03424005) (EudraCT2017-002038-21)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top